Second untreatable superbug infection found in US

Patient in New York infected with a strain of E. coli highly resistant to last-resort antibiotic treatments


A patient in New York has been infected with a strain of E. coli highly resistant to last-resort antibiotic treatments, according to an article on the Becker's Infection Control and Clinical Quality website.

This is the second U.S. patient with the untreatable superbug infection, following a Pennsylvania patient first made public last month.

The mcr-1 gene gives bacteria resistance to colistin, a last-line-of-defense antibiotic used to combat a number of resistant microorganisms.

Going into 2017, the White House has requested $1.1 billion be allocated to efforts to combat antibiotic resistance in the U.S. 

Read the article.

 

 



July 6, 2016


Topic Area: Infection Control


Recent Posts

Hospitals Are Energy Super-Users. Why Is It So Hard to Modernize Them?

Managers face the ongoing challenge of finding a practical way to fund improvements while competing with capital priorities.


Encompass Health Rehabilitation Hospital of Bangor Officially Opens

Encompass Health Bangor is the company’s first wholly owned hospital in Maine.


Early Entry: Manager's Critical Role in Construction Planning

Facilities managers should seek a seat at the table early to shape decisions that affect operations and continuity of care from the onset.


The Evolution of Lighting in Patient Care

Lighting is a significant investment that healthcare facility managers can make to aid in healing.


HealthPartners and Essentia Health to Combine Organizations

The organizations anticipate the combination will be effective Jan. 1, 2027.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.